Advanced health biotechnologies in Thailand: redefining policy directions

BackgroundThailand faces a significant burden in terms of treating and managing degenerative and chronic diseases. Moreover, incidences of rare diseases are rising. Many of these—such as diabetes, cancer, and inherited inborn metabolic diseases—have no definite treatments or cure. Meanwhile, advanced health biotechnology has been found, in principle, to be an effective solution for these health problems.MethodsQualitative approaches were employed to analyse the current situation and examine existing public policies related to advanced health biotechnologies in Thailand. The results of this analysis were then used to formulate policy recommendations.ResultsOur research revealed that the system in Thailand in relation to advanced health biotechnologies is fragmented, with multiple unaddressed gaps, underfunding of research and development (R&D), and a lack of incentives for the private sector. In addition, there are no clear definitions of advanced health biotechnologies, and coverage pathways are absent. Meanwhile, false advertising and misinformation are prevalent, with no responsible bodies to actively and effectively provide appropriate information and education (I&E). The establishment of a specialised institution to fill the gaps in this area is warranted.ConclusionThe development and implementation of a comprehensive national strategic plan related to advanced health biotechnologies, greater investment in R&D and I&E for all stakeholders, collaboration among agencies, harmonisation of reimbursement across public health schemes, and provision of targeted I&E are specifically recommended.

[1]  R. Mckernan,et al.  Pharma's developing interest in stem cells. , 2010, Cell stem cell.

[2]  S. Panichkul,et al.  Current status of the research ethics committees in Thailand. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[3]  Katrina Armstrong,et al.  Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  M. Esteve,et al.  The creation of innovation through public-private collaboration. , 2012, Revista espanola de cardiologia.

[5]  M. Khoury,et al.  Current priorities for public health practice in addressing the role of human genomics in improving population health. , 2011, American journal of preventive medicine.

[6]  A. Izeta,et al.  Clinical translation of stem cell therapies: a bridgeable gap. , 2010, Cell stem cell.

[7]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[8]  Ethical, legal, and social issues related to genomics and cancer research: the impending crisis. , 2005, Journal of the American College of Radiology : JACR.

[9]  J. Sugarman.  Reflections on Governance Models for the Clinical Translation of Stem Cells , 2010, Journal of Law, Medicine & Ethics.

[10]  P. Thorner,et al.  Angiomyeloproliferative lesions following autologous stem cell therapy. , 2010, Journal of the American Society of Nephrology : JASN.

[11]  D. Gibbons,et al.  Developing a case study model for successful translation of stem cell therapies. , 2010, Cell stem cell.

[12]  F. Longo,et al.  La generación de innovación a través de la colaboración público-privada , 2012 .

[13]  P. Magic.  International Technology Transfer & Intellectual Property Rights , 2003 .

[14]  Crystal Dodson,et al.  Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. , 2011, Personalized medicine.

[15]  D. Sipp,et al.  Monitoring and Regulating Offshore Stem Cell Clinics , 2009, Science.

[16]  Nureddin Ashammakhi,et al.  Topics in Tissue Engineering , 2004 .

[17]  E. Hayden.  Stem cells: The 3-billion-dollar question , 2008, Nature.

[18]  S. Moolasarn.  Thai physicians' perceptions of sources of information about new drugs in terms of amounts of information and trustworthiness. , 2009 .

[19]  Gail Javitt.  Law and policy director Gail Javitt public comments on FDA's Draft Guidance for Industry and FDA Staff: Pharmacogenetic Tests and Genetic Tests for Heritable Markers , 2006 .

[20]  Thinakorn Noree,et al.  Thailand's health workforce : a review of challenges and experiences , 2009 .

[21]  A. Wertheimer,et al.  Sources of information for new drugs among physicians in Thailand , 2007, Pharmacy World & Science.

[22]  A. Culyer.  Health Intervention and Technology Assessment Program , 2014 .

[23]  C Boyer,et al.  The Health On the Net Code of Conduct for medical and health Websites , 1998, Comput. Biol. Medicine.

[24]  Sergio L. Schmukler,et al.  Emerging Market Instability : Do Sovereign Ratings Affect Country Risk and Stock Returns ? , 1997 .

[25]  A. Nagy,et al.  Stem cell therapy for the kidney: a cautionary tale. , 2010, Journal of the American Society of Nephrology : JASN.

[26]  Sissades Tongsima,et al.  Outlook on Thailand's Genomics and Computational Biology Research and Development , 2008, PLoS Comput. Biol..

[27]  Célia Boyer,et al.  Improving the Transparency of Health Information Found on the Internet Through the Honcode: a Comparative Study , 2011, MIE.

[28]  D. Polak.  The delivery of regenerative medicines and their impact on healthcare , 2010 .

[29]  Ken Graves.  Global best practices in medical device procurement – A road map to system success , 2011 .